NEW YORK (GenomeWeb News) – Bio-Rad Laboratories announced after the close of the market on Thursday a commercialization deal with Lamprogen.

Lamprogen, a University of Washington spinout, has granted Bio-Rad exclusive rights to commercialize a class of bright, stable, and non-toxic fluorescent particles. The particles can be used in a broad array of assays and research applications including flow cytometry, Bio-Rad said, adding it expects to commercialize the products in 2013.

The deal also grants Bio-Rad access to future technologies developed by Lamprogen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: epigenetic changes linked with high-altitude pulmonary edema, transcriptome profiling of maize leaf development, and more.

Stanford University researchers are studying top athletes to uncover genes linked to performance.

The UW's Wylie Burke and Dartmouth's Gilbert Welch argue that whole-genome testing may do more harm than good, and a related poll.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.